Trials / Terminated
TerminatedNCT03491150
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 149 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Crenezumab | Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above. |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
- First posted
- 2018-04-09
- Last updated
- 2020-07-13
- Results posted
- 2020-06-09
Locations
66 sites across 16 countries: United States, Australia, Canada, Finland, France, Germany, Hong Kong, Italy, Lithuania, Mexico, Poland, Russia, South Korea, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03491150. Inclusion in this directory is not an endorsement.